Myriad Genetics
MYGN
194 hedge funds and large institutions have $1.74B invested in Myriad Genetics in 2023 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 78 increasing their positions, 61 reducing their positions, and 19 closing their positions.
160% more call options, than puts
Call options by funds: $2.81M | Put options by funds: $1.08M
47% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 19
31% more capital invested
Capital invested by funds: $1.33B → $1.74B (+$410M)
28% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 61
9.38% more ownership
Funds ownership: 101% → 110.38% (+9.4%)
4% more funds holding
Funds holding: 186 → 194 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Glenview Capital Management
New York
|
+$25.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$21.2M |
| 3 |
Morgan Stanley
New York
|
+$19.3M |
| 4 |
BlackRock
New York
|
+$17.8M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$17.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$6.52M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$4.66M |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$3.95M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.48M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$2.09M |
MYGN Hedge Fund Activity: Q4 2023 in Review
194 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q4 2023, worth a combined $1.74B — up 31% from $1.33B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new MYGN positions and 19 closed out — a net gain of 9 holders — while 78 added to existing stakes and 61 trimmed.
The largest buyer was Glenview Capital Management, adding an estimated $25.9M. The largest seller was D.E. Shaw & Co, cutting an estimated $6.52M.
- 194 institutional investors held Myriad Genetics (MYGN) as of Q4 2023, up from 186 in Q3 2023.
- Funds reported $1.74B of Myriad Genetics stock for Q4 2023, up 31% quarter-over-quarter.
- 28 funds opened new Myriad Genetics positions in Q4 2023 and 19 closed out, a net change of +9 holders.
- The largest Myriad Genetics buyer in Q4 2023 was Glenview Capital Management, an estimated $25.9M added.
- The largest Myriad Genetics seller in Q4 2023 was D.E. Shaw & Co, an estimated $6.52M sold.
Based on aggregated 13F filings for Q4 2023.